Absolute risk of progression of SMM to MM or related disorders based on the serum FLC ratio
| . | FLC Ratio . | |||
|---|---|---|---|---|
| 0.25 to 4 . | 0.125 to 0.25, or 4 to 8 . | 0.0312 to 0.125 or 8 to 32 . | Less than 0.0312 or more than 32 . | |
| Patients, no. | 63 | 46 | 93 | 71 |
| Years of follow-up, % (95% CI) | ||||
| 1 | 6.7 (0.1-12.8) | 2.2 (0.0-6.4) | 20.3 (11.5-28.2) | 22.1 (11.5-31.3) |
| 2 | 11.9(3.2-19.8) | 19.3 (6.3-30.5) | 38.4 (27.1-47.9) | 42.7 (29.2-53.5) |
| 5 | 28.1 (14.8-39.4) | 35.3 (18.4-48.7) | 58.0 (45.3-67.8) | 70.9 (56.9-80.3) |
| 10 | 50 (30.9-63.8) | 55.2 (34.5-69.3) | 70.4 (57.0-79.6) | 81.1 (67.3-89.1) |
| Cumulative annual rate of progression, % per y | 5.0 | 5.5 | 7.0 | 8.1 |
| Cumulative annual rate of progression, adjusted for competing risk of death, % per y | 3.6 | 4.5 | 6.0 | 7.1 |
| . | FLC Ratio . | |||
|---|---|---|---|---|
| 0.25 to 4 . | 0.125 to 0.25, or 4 to 8 . | 0.0312 to 0.125 or 8 to 32 . | Less than 0.0312 or more than 32 . | |
| Patients, no. | 63 | 46 | 93 | 71 |
| Years of follow-up, % (95% CI) | ||||
| 1 | 6.7 (0.1-12.8) | 2.2 (0.0-6.4) | 20.3 (11.5-28.2) | 22.1 (11.5-31.3) |
| 2 | 11.9(3.2-19.8) | 19.3 (6.3-30.5) | 38.4 (27.1-47.9) | 42.7 (29.2-53.5) |
| 5 | 28.1 (14.8-39.4) | 35.3 (18.4-48.7) | 58.0 (45.3-67.8) | 70.9 (56.9-80.3) |
| 10 | 50 (30.9-63.8) | 55.2 (34.5-69.3) | 70.4 (57.0-79.6) | 81.1 (67.3-89.1) |
| Cumulative annual rate of progression, % per y | 5.0 | 5.5 | 7.0 | 8.1 |
| Cumulative annual rate of progression, adjusted for competing risk of death, % per y | 3.6 | 4.5 | 6.0 | 7.1 |